Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm|Hormone Receptor Positive Breast Carcinoma
Interventions: DRUG: Abemaciclib|DRUG: Fulvestrant
Sponsor: University of California, Irvine
Collaborators: Eli Lilly and Company